Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-318090

ABSTRACT

Background: The rapid outbreak of Coronavirus diseases (COVID-19) originating in Wuhan, China, and the subsequent declaration of a state of “pandemic” on March 11, 2020 has necessitated a widespread global response to manage and control the transmission, spread and impact of COVID-19. Mobile technology has been leveraged in a number of ways to control the spread of COVID-19, including to support knowledge translation. Mobile applications are accessible, acceptable, easily adopted, and have the ability to support social distancing efforts. The following review assesses the mobile applications currently available to address COVID-19 and seeks existing studies in the literature that evaluate such applications. Methods: 3 databases (Embase, Web of Science and PubMed), 2 application stores (GooglePlay and Apple’s App Store) and google search engine were searched from inception until April 05, 2020 using key words and search strings to identify relevant apps and/or literature. Reviews of the obtained results were examined by two reviewers in double-blind nature and assessed for inclusion or exclusion. Results: : 36 studies, 72 websites and 312 mobile-based applications were identified through searches. 14 applications met the inclusion criteria and were analyzed. Additional eHealth tools identified through the search strategy were considered for supplemental analysis (including online dashboards and applications not available through application stores). Conclusion: This review provides a brief assessment of the goals of applications addressing COVID-19, the types of approaches being used by these applications, and draws conclusions on the needs not being met by such application-based interventions. Innovation and collaboration between government, healthcare organizations and application developers is needed to address the identified gaps and facilitate the successful harnessing of mobile applications in the management of COVID-19.

2.
BMJ Open ; 11(12), 2021.
Article in English | ProQuest Central | ID: covidwho-1592612

ABSTRACT

IntroductionTreatment of bipolar disorder is the focus of several clinical trials, however the understanding of the outcomes for establishing treatment effectiveness within these trials is limited. Further, there is limited literature which reports on the outcomes considered to be important to patients, indicating that patient perspectives are often not considered when selecting outcomes of effectiveness within trials. This protocol describes a systematic review which aims to describe the outcomes being used within trials to measure treatment effectiveness, commenting on the inclusion of patient-important outcomes within previous trials.Methods and analysisThis protocol is reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols statement. OVID MEDLINE, OVID Embase, OVID APA PsycINFO, Web of Science, the Wiley Cochrane Library, ClinicalTrials.gov and the International Clinical Trials Registry Platform databases will be searched for eligible studies. Screening, full-text and data extraction stages will be completed in duplicate using the Covidence platform for systematic reviews. Eligible studies will include clinical trials of interventions in bipolar disorder, in order to identify outcomes used to assess treatment effectiveness, and qualitative studies, to determine which outcomes have been reported as important by patients. Risk of bias for included studies will be assessed using the Cochrane Risk of Bias Tool for randomised controlled trials, and the Newcastle-Ottawa Scale for observational research.Ethics and disseminationThis review will involve dissemination to key stakeholders, including primary end users such as patients, clinicians and trialists. Knowledge translation tools will be generated to share the relevant conclusions of this review. Results will be communicated to the scientific community through peer-reviewed publications, conferences and workshops. No ethics approval will be sought as this study is based on literature.PROSPERO registration numberCRD42021214435.

3.
J Med Case Rep ; 15(1): 586, 2021 Dec 13.
Article in English | MEDLINE | ID: covidwho-1571926

ABSTRACT

BACKGROUND: Psychiatric disorders increase risk of neuropsychiatric disease and poor outcomes, yet little is known about the neuropsychiatric manifestations of COVID-19 in the psychiatric population. The primary objective is to synthesize neuropsychiatric outcomes of COVID-19 in people with preexisting psychiatric disorders. METHODS: Data were collected during an ongoing review of the impact of pandemics on people with existing psychiatric disorders. All study designs and gray literature were included. Medline, PsychInfo, CINAHL, EMBASE, and MedRx were searched from inception to September 1 2020. Risk of bias was assessed using a published tool that can accommodate all study types. Two independent authors screened the studies and extracted data. Data were narratively synthesized, as there were insufficient data to meta-analyze. Evidence was appraised according to GRADE. RESULTS: Four case reports were included, comprising 13 participants from three countries. Many large-sample, relevant papers were omitted for not reporting psychiatric history, despite reporting other comorbidities. Included participants (n = 13) were hospitalized with COVID-19 and appeared to meet criteria for delirium. Myoclonus, rigidity, and alogia were also reported. The most commonly reported preexisting psychiatric diagnoses were mood disorders, schizophrenia, and alcohol use disorder. CONCLUSIONS: People with preexisting psychiatric disorders may experience delirium, rigidity, myoclonus, and alogia during COVID-19 infection; although higher quality and longitudinal data are needed to better understand these phenomena. Relevant COVID-19 literature does not always report psychiatric history, despite heightened neuropsychiatric vulnerability within this population. TRIAL REGISTRATION:  PROSPERO (CRD42020179611).


Subject(s)
COVID-19 , Delirium , Bias , Delirium/epidemiology , Humans , Pandemics , SARS-CoV-2
4.
Syst Rev ; 9(1): 200, 2020 09 01.
Article in English | MEDLINE | ID: covidwho-1456001

ABSTRACT

BACKGROUND: The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance. METHODS: The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. DISCUSSION: This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. SYSTEMATIC REVIEW REGISTRATION: This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121).


Subject(s)
Analgesics, Opioid , Genome-Wide Association Study , Opioid-Related Disorders , Analgesics, Opioid/therapeutic use , Humans , Meta-Analysis as Topic , North America , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/genetics , Systematic Reviews as Topic , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL